» Articles » PMID: 36143043

The Assessment of Serum Cytokines in Oral Squamous Cell Carcinoma Patients: An Observational Prospective Controlled Study

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Sep 23
PMID 36143043
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The oral squamous cell carcinoma (OSCC) tumor microenvironment (TME) is a complex interweb of cells and mediators balancing carcinogenesis, inflammation, and the immune response. However, cytokines are not only secreted within the TME but also released by a variety of other cells that do not comprise the TME; therefore, a thorough assessment of humoral changes in OSCC should include the measurement of serum cytokines. Methods: We assessed the role of various serum cytokines in the evolution of OSCC, before and after treatment, versus a control group. We measured the serum concentrations of MIP-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, and TNF-α. Results: Significantly higher values (p < 0.01) were noted for IL-1β, IL-6, IL-8, IL-10, and TNF-α in the OSCC group before treatment (n = 13) compared with the control group (n = 14), and the increased concentrations persisted after treatment (n = 11). Furthermore, the variations in the values of MIP-1α, IL-1β, IL-10, and TNF-α are correlated both before and after treatment (p < 0.01). In the pretherapeutic group, IL-6 and IL-8 concentrations also correlate with IL-1β and IL-10 serum levels (p < 0.01), while in the posttherapeutic group, IL-4 varies with MIP-1α and TNF-α (p < 0.01). Conclusion: In OSCC patients, serum cytokine levels are significantly higher compared with control, but they are not significantly altered by treatment, therefore implying that they are also influenced by systemic factors. The interactions between all involved cytokines and the various pathways they regulate warrant further studies to clarify their definitive roles.

Citing Articles

Serum Pro-Inflammatory Cytokines and Leptin as Potential Biomarkers for Treatment Response and Toxicity in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Alrehaili A, Gharib A, Bakhuraysah M, Alharthi A, Alsalmi O, Ali Alsaeedi F Diseases. 2024; 12(3).

PMID: 38534979 PMC: 10969547. DOI: 10.3390/diseases12030055.


Current Approach and Future Directions in the Diagnosis and Prognosis of Keratinocyte Carcinomas.

Scheau C, Caruntu C, Caruntu A J Clin Med. 2023; 12(12).

PMID: 37373672 PMC: 10299315. DOI: 10.3390/jcm12123974.


Identification and validation of neurotrophic factor-related genes signature in HNSCC to predict survival and immune landscapes.

Peng G, Chi H, Gao X, Zhang J, Song G, Xie X Front Genet. 2022; 13:1010044.

PMID: 36406133 PMC: 9672384. DOI: 10.3389/fgene.2022.1010044.

References
1.
Zhang C, Zhu M, Wang W, Chen D, Chen S, Zheng H . TNF-α promotes tumor lymph angiogenesis in head and neck squamous cell carcinoma through regulation of ERK3. Transl Cancer Res. 2022; 8(6):2439-2448. PMC: 8798551. DOI: 10.21037/tcr.2019.09.60. View

2.
Caruntu A, Scheau C, Tampa M, Georgescu S, Caruntu C, Tanase C . Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. Adv Exp Med Biol. 2021; 1335:11-35. DOI: 10.1007/5584_2021_626. View

3.
Raeburn C, Sheppard F, Barsness K, Arya J, Harken A . Cytokines for surgeons. Am J Surg. 2002; 183(3):268-73. DOI: 10.1016/s0002-9610(02)00781-x. View

4.
Jebreel A, Mistry D, Loke D, Dunn G, Hough V, Oliver K . Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol. 2006; 121(3):246-52. DOI: 10.1017/S0022215106002428. View

5.
Kavasi R, Neagu M, Constantin C, Munteanu A, Surcel M, Tsatsakis A . Matrix Effectors in the Pathogenesis of Keratinocyte-Derived Carcinomas. Front Med (Lausanne). 2022; 9:879500. PMC: 9100789. DOI: 10.3389/fmed.2022.879500. View